UCB Phrama France Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company reoriented in the direction of biopharmaceuticals by moving away from chemicals and divesting from OTCs. As you have worked on the strategy and policy at headquarters in addition to…
Boehringer Ingelheim Brazil You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three years, my assignment was to open this company and to integrate it more with Brazil. We have a quite enlightened…
Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…
Boehringer Ingelheim Italy The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could you describe the role of each entity together with its contribution to resources and growth? Boehringer Ingelheim itself is responsible…
Boehringer Ingelheim Mexico You arrived to the position of Boehringer Ingelheim Mexico’s General Director in 2010, what are some of the most exciting milestones and achievements you have presided over during this time? I’ve been in the company for 18 years, and came back from Germany in 2010 to become the company’s first…
Boehringer Ingelheim Chile What have been Boehringer Ingelheim’s major milestones and achievements since your establishment in Chile? Chile, in the regional context, represents a very important market with a solid evolution in terms of sales. For our company, on a regional scale, the country has been growing above the average rate of 15.6%…
Boehringer Ingelheim Hungary Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right after the fall of the Iron Curtain… Can you provide our readers with a better idea of the role that…
Boehringer Ingelheim Romania If we take a look back at Boehringer Ingelheim’s dynamic growth path in the Romanian market, we see an evolution from a one-man show in the 1990s to a present day subsidiary of over 100 people. What have been the key milestones and achievements for you since joining this subsidiary…
Boehringer Ingelheim Russia You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you have stayed with Boehringer Ingelheim throughout executive positions in Germany, Portugal, Ukraine, Finland, and, of course, now Russia. What has…
Boehringer Ingelheim India Pvt. Ltd. Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group, there are the mature and emerging markets for the prescription medicines. Within this structure, India falls into the emerging markets…
Office for the Strategic Coordination of Health Research (OSCHR) It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some examples of the new way forward. According to you, what are the factors that drove Government to pursue such drastic…
Boehringer Ingelheim France There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these new facilities here at Paris Biopark. What does this express about the moves Boehringer Ingelheim is taking in France and…
See our Cookie Privacy Policy Here